Nuvation Bio Inc.
NUVB
Jodie situation report
Nuvation Bio Inc.'s move is spreading beyond its market group.
No new filing conclusion is available. 23 of 23 group members are active now; 1 filing-linked outsider is moving with the group, and 0 of 6 directly disclosed connections are confirming.
- At least 15 of 23 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- BMRN remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 8 of 23 members or fewer.
Who this business touches
The relationships behind NUVB
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
IVBXFFiling-linked namepartnerMar 2, 2026 ▾
“Taletrectinib is being commercialized in Japan by our partner NK under the brand name IBTROZI and in China by our partner Innovent under the brand name DOVBLERON®.”
AZNAstraZeneca PLCcompetitorMar 2, 2026 ▾
“There are many other companies that have commercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company (“BMS”), Eli Lilly, Merck, Novartis Phar…”
NUVLNuvalent InccompetitorMar 2, 2026 ▾
“Other ROS1 inhibitors currently in clinical-stage development include Nuvalent’s zidesamtinib.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
NUVB is currently a Participant in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.